InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,669.59
(
1.24%
)
Post# of 5055
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Ubertino

Send PM Follow Ignore
Followers 113
Posts 25553
Boards Moderated 4
Alias Born 02/01/2004

Ubertino

Re: None

Friday, 09/22/2006 11:46:26 AM

Friday, September 22, 2006 11:46:26 AM

Post# of 5055
Re--[0033] hi(sic) a preferred embodiment, the therapeutically active compound that inhibits viral infection or production in a mammal comprises Tubercin, Tubercin-3, Tubercin-5, Tubercin-7, SSM (otherwise known as SSMA or Specific Substance of Maruyama), or Z- 100 or any combination thereof, hi(sic) yet another preferred embodiment, the agent that inhibits viral infection or production in a mammal comprises a Tubercin, Tubercin-3, Tubercin-5, Tubercin-7, SSM, or Z-100-based oligosaccharide-protein conjugate or lipid arabinomannan-protein conjugate or any combination thereof.--

From PubMed:
1: Antivir Ther. 2006;11(3):297-303. Links
The safety and tolerability of Z-100 in patients infected with HIV-1.Borucki M, Holodniy M, Pierone G Jr, Ruane P, Steinhart C, Williams S, Slom T, Palella F Jr, Hare CB, Yoshidao Y, Li XD, Pollard RB.
University of Texas, Tyler, TX, USA.

Z-100 is an extract of the Mycobacterium tuberculosis strain Aoyama B, which contains various polysaccharides. Aoyama B has previously been shown to induce a T helper 1-type cytokine response in various murine oncological models and has also demonstrated inhibitory activity against HIV-1 in vitro. This multicentre study primarily determined the safety of Z-100 in early HIV-1-infected patients who were treatment naive; were treatment experienced, but had elected to discontinue highly active antiretroviral therapy (HAART) 8 weeks or longer before the study; or were stable on their first or second HAART regimen for at least 12 weeks before the study. Thirty-two individuals participated in this study and self-injected either placebo, 20 microg or 40 microg Z-100 twice a week for 8 weeks. Z-100 was well tolerated and the safety profiles of the Z-100 treatment groups were not meaningfully different compared with the placebo group. Plasma levels of HIV-1 RNA were not statistically significantly different in any treatment group at the end of the treatment period. There were no statistically significant differences among the treatment groups in the change from baseline to week 8 for any of the biological endpoints including plasma levels of HIV-1 RNA; CD4+ and CD8+ T-cell counts; levels of macrophage inflammatory protein 1; soluble tumour necrosis factor receptor 1; C-reactive protein; interleukin-6; and granulocyte colony stimulating factor. Consequently, this trial demonstrates the safety of Z-100 in HIV-1 infected patients without evidence of any activity at the doses administered.

PMID: 16759045 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...


It is clear that Z-100/SSM/SSMA/Specific Substance of Maruyama is well known anti-viral agent. By what stretch of the imagination does anyone think this sham application will ever get patented!? It just ain't goin to happen.

See also:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

The SEC Must Go!
And jail shorters.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up